RxDoctor Payments Data

Dawn Gadon

Family · Somers Point, NJNPI 1134227937

Payments from drug & device makers

$1,298in general payments, 2019–2025

Across 87 payments — averaging $14.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$217
  • Amgen$145
  • Alkermes, Inc.$135
  • Novo Nordisk$132
  • Lilly USA, LLC$110
  • Johnson & Johnson$108
  • plus $450 from 10 others

What the payments were for

  • Food & beverage$1,298100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,298 in reported general payments places this provider in the 80th percentile of 2,692 family providers in New Jersey.

See all family providers in New Jersey

Medicare billing

Part B allowed, 2024
$6,382
Medicare patients
50
Services billed
76

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin25$27,157
Breo ElliptaFluticasone/Vilanterol23$9,416
EliquisApixaban11$6,342
Atorvastatin Calcium223$2,815
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl37$2,741
VascepaIcosapent Ethyl13$2,264
Omega-3 Acid Ethyl Esters15$1,844
Aripiprazole17$1,680
Albuterol Sulfate HfaAlbuterol Sulfate48$1,259
Naltrexone Hcl14$1,190
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$1,086
Levothyroxine Sodium113$1,048
Olmesartan Medoxomil24$1,002
Omeprazole56$970
Rosuvastatin Calcium56$919

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$217$27,15725 claims
GSKBreo Ellipta$17$9,41623 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,692 family providers in New Jersey.

Other family in Somers Point

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →